Drug Discovery News: Breaking Drug Discovery News, Comments and Articles. - Page: 4

22:01 EDT 1st September 2014 | BioPortfolio

Drug Discovery News - Page: 4Twitter RSS

Read the latest Drug Discovery News from around the world, updated every five minutes. Breaking stories from leading news and press agencies, bloggers and experts on Drug Discovery.

Search or Follow Our Drug Discovery - Page: 4 News…

If you are looking for more stories, you may wish to search our extensive news archives for relevant stories: Search for More Drug Discovery - Page: 4 News.
You can also follow our Drug Discovery - Page: 4 news stories on Twitter: @DiscoveryDrug

Showing "drug drug discovery discovery" News Articles 76 to 100 of 28,000+

Sunday 31st August 2014

Pfizer and Protalix’s Elelyso receives FDA approval to treat type 1 Gaucher disease

Pfizer and Protalix BioTherapeutics have secured approval from the US Food and Drug Administration (FDA) for Elelyso (taliglucerase alfa) to treat paediatric patients with type 1 Gaucher disease.

U.S. FDA Grants QIDP Status for Wockhardt Anti-Infective Drug Discovery Program

PARSIPPANY, N.J., Aug. 31, 2014 /PRNewswire/ -- Wockhardt Limited today announces a major boost to the New Drug Discovery program in Anti-Infective research when two of its drugs, WCK 771 and WCK 2349, received the coveted Qualified Infectious Disease Product (QIDP) status from U.S. Food & Drug Administration (FDA).  QIDP status is granted to drugs which act against pathogens which have a...

Daiichi Sankyo Further Expands TaNeDS Collaborative Drug Discovery Program in Europe

TOKYO, Sept. 1, 2014 /PRNewswire/ -- Daiichi Sankyo Company, Limited (Tokyo Stock Exchange: 4568; hereafter Daiichi Sankyo) announced on September 1 details of the application for its Take a New Challenge for Drug Discovery (TaNeDS) Global Programme 2014, a collaborative drug discovery initiative for universities and research institutes in Europe. The TaNeDS program was launched in Japan in 2011 ...

Actos Lawsuit News: Federal Judge Won’t Dismiss $9 Billion Verdict in First Federal Actos Bladder Cancer Trial, Bernstein Liebhard LLP Reports

The Firm is evaluating Actos lawsuits on behalf of individuals who developed bladder cancer, allegedly due to long-term use of the Type 2 diabetes drug. New Yor, New York (PRWEB) August 31, 2014 The federal judge overseeing thousands of Actos bladder cancer lawsuits (http://www.theactoslawsuitcenter.com/) in the U.S. District Court, Western District of Louisiana has refused to overturn a $9 bill...

China Allows Production Of Ebola Drug In Emergency Military Cases

China authorities have cleared production of JK-05 as an emergency Ebola treatment for members of the People's Liberation Army while clinical trials are conducted to see if it could be more widely available.

Wockhardt Drug Gets India's First U.S. QIDP Fast-Track Status

Wockhardt has become the first India drug maker to receive U.S. FDA Qualified Infectious Disease Product status, a fast-track review designation, for two versions of its anti-MRSA drug.

Heart drug launch could be 'most exciting ever', says Novartis

BARCELONA (Reuters) - The expected launch of Novartis's new heart failure drug next year promises to be the company's most exciting ever and profit margins on the medicine will be good, its head of pharmaceuticals said on Sunday.

Heart drug launch could be "most exciting ever", says Novartis

BARCELONA, Aug 31 (Reuters) - The expected launch of Novartis's new heart failure drug next year promises to be the company's most exciting ever and profit margins on the medicine will be good, its head of pharmaceuticals said on Sunday.

Novartis' investigational heart failure drug LCZ696 shows striking efficacy

Swiss drug major Novartis on Saturday presented striking new data for its LZC696 heart drug at the European Society of Cardiology congress being held in Barcelona, Spain, and published simultaneously in the New England Journal of Medicine.

Study raises concerns over Servier, Amgen heart drug

BARCELONA (Reuters) - A major clinical study has raised concerns about a drug from private French company Servier that helps lower the heart rate and which was licensed to U.S. group Amgen last year.

Takeda and Lilly fail to overturn $9 billion award for hiding cancer risk of Actos

Japan’s largest drugmaker Takeda Pharmaceutical and US pharma major Eli Lilly have failed in their attempt to overturn a combined $9 billion punitive damage award by a US jury for hiding cancer risks associated with their diabetes drug Actos (piog...

Estrogen May Be Key to Anti-Binge Tx (CME/CE)

(MedPage Today) -- Researchers have identified a receptor that mediates the effect of estrogen to suppress binge eating, and the discovery could potentially lead to effective treatments for the disorder.

Experimental drug for Ebola

An international team of scientists has successfully treated the Ebola virus in monkeys with the experimental drug ZMapp. The treatment resulted in recovery in 100% of the 18 rhesus macaques treated. Three untreated monkeys died by day eight of the trial. However, those monkeys on ZMapp recovered, even with clinical symptoms such as liver dysfunction and haemorrhaging and when treated up to ...

Defendant Dismissed from Pennsylvania Vaginal Mesh Lawsuits, Bernstein Liebhard LLP Reports

The Firm is representing hundreds of clients in transvaginal mesh lawsuits filed against American Medical Systems, Inc., Boston Scientific Corp., C.R. Bard, Inc. and Ethicon, Inc. New York, NY (PRWEB) August 31, 2014 Secant Medical LLC, a manufacturer of polypropylene mesh used in pelvic mesh implants, has been dismissed from hundreds of vaginal mesh lawsuits (http://www.transvaginalmeshlawsuithe...

ESC: Evidence Mounts for Injection to Lower LDL-C (CME/CE)

BARCELONA (MedPage Today) -- Four studies testing the injectable novel lipid-lowering agent alirocumab found the drug dramatically reduced LDL-cholesterol (LDL-C) among high-risk patients who had not achieved LDL targets using maximum tolerated stati...

Novartis heart failure drug set to revolutionise treatment

Novartis heart failure drug set to revolutionise treatment

Gene clues to glaucoma risk

Scientists on Sunday said they had identified six genetic variants linked to glaucoma, a discovery that should help earlier diagnosis and better treatment for this often-debilitating eye disease.

Discovery reveals how bacteria distinguish harmful versus helpful viruses

When they are not busy attacking us, germs go after each other. But when viruses invade bacteria, it doesn't always spell disaster for the infected microbes: Sometimes viruses actually carry helpful genes that a bacterium can harness to, say, expand ...

59 new drug applications pending review at CDSCO

Biospectrum [Read more]

Early data suggest Sanofi, Regeneron drug may halve heart risk

BARCELONA (Reuters) - An experimental cholesterol-lowering drug from Sanofi and Regeneron Pharmaceuticals roughly halved the number of heart attacks and strokes in a clinical trial, researchers reported on Sunday.

Colchicine 'Useless' for Postop Pericardial Effusion: POPE-2

In yet another trial, colchicine did not reduce complications after cardiac surgery; specifically, the drug failed to decrease postoperative pericardial effusion volume or prevent cardiac tamponade. Heartwire

New Street Drug Found to be Much More Powerful Than Heroin

USA (PRWEB) August 31, 2014 According to an article posted in Medical News Today (8/21), entitled Emerging Street Drug Fifteen Times Stronger than Heroin , a new opiate has begun to hit the streets of America which is fifteen times more potent th...

Week in Review: ZAI Laboratory Lands $30 Million in Initial Funding

ZAI Laboratory, a Shanghai startup with two drug candidates in-licensed from Sanofi, raised more than $30 million from an international group of healthcare investors; FortuneRock(China) of Beijing closed a $24 million funding from China investors to ...

Saturday 30th August 2014

HTL Discovery Pro pipettes

HTL has launched the Discovery Pro pipette - a product with low mass and light piston actions. The body of the pipette is carefully engineered to comfortably accommodate those with large or small hand shapes and sizes. The product’s contoured shape eases the required grip strength, and is said to make pipetting motions effortless. The tip ejection force is said to have been reduced by more ...

Enzo Life Sciences Chemilum de Lys HDAC/SIRT Chemiluminescent Drug Discovery Kit

The Chemilum de Lys HDAC/SIRT Chemiluminescent Drug Discovery Kit enables reproducible, high-throughput screening of HDAC or SIRT inhibitors using a novel substrate that closely mimics the natural in vivo substrate. The drug discovery kit is a complete assay system designed to measure histone deacetylase (HDAC) and sirtuin activity in cell or nuclear extracts, immunoprecipitates or purified enzym...


Search BioPortfolio:
Advertisement
Advertisement

News Quicklinks